Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-03-06 00:00:00 ET · period of report 2024-03-04 · accession 0001787306-24-000042 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-06 | 2024-03-04 | ARQT | Matsuda Masaru | See Remark | S - Sale | $11.12 | -3,760 | 190.4K | -2% | -$41.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-04 | S | D | 3,760 | $11.12 | 190,424 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |